logo

Market access is hard. Let’s make it easier.

We’ve been there. We’ve done it. We’ve got the t-shirt. We know how tough market access can be.
We’re here to make it easier. To get to the best insights, you need the best people and the best data. Our pharma experts go above and beyond to uncover the powerful, market-defining insights you need.

How and when we can help

EARLY STAGE
PRE-CLINICAL (P1)
LATE STAGE
P2 AND P3
LAUNCH
POST-LAUNCH
CONSULTING
PAYER AND KEY OPINION LEADERS RESEARCH/AD-BOARDS
COMPETITIVE INTELLIGENCE (PIPELINE, HTA, EVIDENCE, PRICE DRIVERS)
PRICE DISCOVERY
PRICE AND LAUNCH STRATEGY
PRICE PROTECTION/IRP ANALYSIS
EVIDENCE GAP ANALYSIS
HTA TRACKING
MULTI-INDICATION VALUE ASSESSMENTS
REVENUE OPTIMISATION MODELS
ANALOGUE ANALYSIS
LAUNCH SEQUENCE ANALYSIS
DUE DILIGENCE ASSESSMENTS
COMPETITIVE WORKSHOPS/SUMMITS

Find out more about our services and products. Download our capabilities deck today and find out why you should add us to your RFP shortlist.

Our global reach

Our consulting services

Group 3
Pricing and launch strategy

Optimise your pricing strategy and learn from in-depth qualitative and quantitative price assessments.

Group 4
Evidence gap
analysis

Find gaps in your evidence by testing with our extensive payer network spanning 40+ countries.

Group 1
Multi-indication price
optimisation

Target your optimal price and assess the value of products in multiple indications.

Vector12
Fast due
diligence

Get rapid due diligence assessments – conducted with the attention and expertise they deserve.

Layer_1_00000161600219733206747040000003628489028405775010_
Analogue
analysis

Unlock rigorous secondary research and analogue analysis using our own BI solution, Nuro.

Layer_1_00000047740200481459042450000017212005669851084988_
Revenue optimisation
Excel tools

Go deeper with our revenue optimis-ation, budget impact, IRP and sce-nario comparison tools.

Our clients love what we do

Access Infinity provided excellent in-depth insights and guidance in key global markets. I’ve been very pleased with their responsiveness and the quality of work

Kevin La Wall Commercial Director, Infectious Diseases, GSK

The analyses was great and very well done! The work was quite robust and thorough given such incredibly short timelines!

Ellison Suthoff Sage Therapeutics, US
    Our consulting work in numbers
    0 +
    Hours of payer & KOL interviews conducted in-house
    1000 +
    Consulting projects